Iparomlimab/Tuvonralimab Plus Chemo ± Bevacizumab Yields Responses in Recurrent/Metastatic Cervical Cancer
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
Tremelimumab Plus Paclitaxel Generates Responses in Refractory Metastatic Urothelial Cancer
Pembrolizumab Plus SBRT Fails to Improve Survival in Unresected Stage I/II NSCLC
Retifanlimab Emerges as Potential New SOC in Advanced SCAC
Novel BTK Degrader NX-5948 Yields High Response Rates in Pretreated CLL/SLL
Mount Sinai Researchers Identify Six-Gene Pattern to Predict Drug Success in Multiple Myeloma Patients
EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma
2 Commerce Drive
Cranbury, NJ 08512